Limits...
An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Vodopivec DM, Rubio JE, Fornoni A, Lenz O - Case Rep Med (2012)

Bottom Line: We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day.Then, we looked for new reported cases from 2004 to present day.All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology and Hypertension, Jackson Memorial Hospital, 1611 North West 12th Avenue, Miami, FL 33101, USA.

ABSTRACT
Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms from these citations in MEDLINE to find additional publications. We relied on a literature review published in 2003 by Baeksgaard et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to present day. All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

No MeSH data available.


Related in: MedlinePlus

Etiology of tumor lysis syndrome. TACE: transarterial chemoembolization. Others include surgery, bisphosphonates, radiofrequency, combination of different cancer therapies.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3368228&req=5

fig1: Etiology of tumor lysis syndrome. TACE: transarterial chemoembolization. Others include surgery, bisphosphonates, radiofrequency, combination of different cancer therapies.

Mentions: Tumor lysis syndrome develops usually after the initiation of chemotherapy but in rare cases may arise spontaneously before any antitumor therapy has been initiated [1, 4–19] (Table 1) (Figure 1). TLS is common in patients with hematologic malignancies with high growth rates or a large disease burden, but it is rarely observed in patients with solid tumors of which to date there are only 100 cases described in the literature [1–93] (Table 1) (Figure 2).


An unusual presentation of tumor lysis syndrome in a patient with advanced gastric adenocarcinoma: case report and literature review.

Vodopivec DM, Rubio JE, Fornoni A, Lenz O - Case Rep Med (2012)

Etiology of tumor lysis syndrome. TACE: transarterial chemoembolization. Others include surgery, bisphosphonates, radiofrequency, combination of different cancer therapies.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3368228&req=5

fig1: Etiology of tumor lysis syndrome. TACE: transarterial chemoembolization. Others include surgery, bisphosphonates, radiofrequency, combination of different cancer therapies.
Mentions: Tumor lysis syndrome develops usually after the initiation of chemotherapy but in rare cases may arise spontaneously before any antitumor therapy has been initiated [1, 4–19] (Table 1) (Figure 1). TLS is common in patients with hematologic malignancies with high growth rates or a large disease burden, but it is rarely observed in patients with solid tumors of which to date there are only 100 cases described in the literature [1–93] (Table 1) (Figure 2).

Bottom Line: We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day.Then, we looked for new reported cases from 2004 to present day.All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

View Article: PubMed Central - PubMed

Affiliation: Department of Nephrology and Hypertension, Jackson Memorial Hospital, 1611 North West 12th Avenue, Miami, FL 33101, USA.

ABSTRACT
Tumor lysis syndrome (TLS) is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and secondary hypocalcemia in patients with a malignancy. When these laboratory abnormalities develop rapidly, clinical complications such as cardiac arrhythmias, acute renal failure, seizures, or death may occur. TLS is caused by rapid release of intracellular contents by dying tumor cells, a condition that is expected to be common in hematologic malignancies. However, TLS rarely occurs with solid tumors, and here we present the second chemotherapy-induced TLS in a patient with advanced gastric adenocarcinoma to be reported in the literature. We also provide information regarding the total cases of TLS in solid tumors reported from 1977 to present day. Our methodology involved identifying key articles from existing reviews of the literature and then using search terms from these citations in MEDLINE to find additional publications. We relied on a literature review published in 2003 by Baeksgaard et al., where they gathered all total 45 cases reported from 1977 to 2003. Then, we looked for new reported cases from 2004 to present day. All reports (case reports, brief reports, letters to editor, correspondence, reviews, journals, and short communications) identified through these searches were reviewed and included.

No MeSH data available.


Related in: MedlinePlus